Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Piroxicam betadex - Chiesi

Drug Profile

Piroxicam betadex - Chiesi

Alternative Names: Beta-cyclodextrin piroxicam; Brexecam; Brexidol; Brexin; Brexine; Brexinil; CHF 1194; Cicladol; Cycladol; Flogene; Piroxicam beta-cyclodextrin; Piroxicam beta-cyclodextrin complex; Solocalm Rapido

Latest Information Update: 12 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi
  • Class Antirheumatics; Beta-Cyclodextrins; Carbohydrates; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Dysmenorrhoea; Gout; Inflammation; Musculoskeletal disorders; Osteoarthritis; Pain; Rheumatic disorders; Rheumatoid arthritis
  • No development reported Migraine; Tension type headache

Most Recent Events

  • 12 Feb 2019 Chemical structure information added
  • 16 Apr 2004 Amersham has merged with GE Medical Systems to form GE Healthcare
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top